Smith & Nephew plc  

(Public, LON:SN)   Watch this stock  
Find more results for SN
866.00
+5.50 (0.64%)
Apr 17 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 862.50 - 872.10
52 week 715.00 - 964.00
Open 866.00
Vol / Avg. 1.79M/2.22M
Mkt cap 7.74B*
P/E 23.69
Div/yield 10.16/1.85*
EPS 0.37*
Shares 894.32M
Beta     -
Inst. own     -
*GBP
May 1, 2014
Q1 2014 Smith & Nephew Earnings Conference Call - 8:30AM GMT+1 - Add to calendar
May 1, 2014
Q1 2014 Smith & Nephew Earnings Release - 7:00AM GMT+1 - Add to calendar
Apr 10, 2014
Smith & Nephew Annual Shareholder Meeting
Mar 11, 2014
Smith & Nephew at Canaccord Genuity's Musculoskeletal Conference
Mar 4, 2014
Smith & Nephew at Credit Suisse Healthcare Conference
Feb 6, 2014
Q4 2013 Smith & Nephew Earnings Conference Call - Webcast
Feb 6, 2014
Q4 2013 Smith & Nephew Earnings Release
Feb 3, 2014
Smith & Nephew to Acquire ArthroCare Corp Conference Call - Webcast
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 13.79% 12.78%
Operating margin 20.00% 18.62%
EBITD margin - 30.41%
Return on average assets 11.41% 9.70%
Return on average equity 16.33% 14.02%
Employees 11,000 -
CDP Score - 92 B

Address

15 Adam Street
LONDON, ENG WC2N 6LA
United Kingdom - Map
+44-20-74017646 (Phone)
+44-20-79303353 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (which includes arthroscopic procedures referred to as sports medicine) and advanced wound management. It operates in three segments: Orthopaedics, Endoscopy and Advanced Wound Management. It operates on a worldwide basis and has distribution channels in over 90 countries. Orthopaedic reconstruction implants include hip, knee and shoulder joints, as well as ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. Endoscopy business develops and commercialises endoscopic (minimally invasive surgery) techniques, educational programmes and services. Advanced Wound Management business offers a range of products from initial wound bed preparation through to full wound closure. In May 2012, it acquired Kalypto Medical, Inc. In December 2012, the Company acquired the assets of Healthpoint Biotherapeutics.

Officers and directors

Olivier Bohuon Chief Executive Officer, Executive Director
Age: 52
Julie Brown Chief Financial Officer, Executive Director
Age: 50
Michael G. Frazzette President - Advanced Surgical Devices
Age: 50
Kelvin Johnson President - International Markets
Age: 61
Roger Teasdale President - Advanced Wound Management
Age: 45
Francisco Canal Vega President - Emerging Markets
Age: 51
R. Gordon Howe Senior Vice President - Global Planning and Development
Age: 50
Ros Rivaz Chief Technology Officer
Age: 57
John W. Campo Chief Legal Officer
Age: 58
Helen Maye Chief Human Resources Officer
Age: 53